Evercore Wealth Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Evercore Wealth Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-354	Closed	-$32K	–	616
2017 Q4	$32K	Hold	354	–	–	﹤0.01%	644
2017 Q3	$16K	Hold	354	–	–	﹤0.01%	741
2017 Q2	$6K	Hold	354	–	–	﹤0.01%	883
2017 Q1	$5K	Hold	354	–	–	﹤0.01%	880
2016 Q4	$5K	Hold	354	–	–	﹤0.01%	887
2016 Q3	$4K	Sell	354 -3	-0.8%	-$29	﹤0.01%	958
2016 Q2	$3K	Hold	357	–	–	﹤0.01%	981
2016 Q1	$3K	Hold	357	–	–	﹤0.01%	905
2015 Q4	$4K	Buy	357 +178	+99%	+$4.88K	﹤0.01%	942
2015 Q3	$12K	Hold	179	–	–	﹤0.01%	811
2015 Q2	$12K	Hold	179	–	–	﹤0.01%	872
2015 Q1	$12K	Hold	179	–	–	﹤0.01%	849
2014 Q4	$16K	Hold	179	–	–	﹤0.01%	695
2014 Q3	$20K	Hold	179	–	–	﹤0.01%	738
2014 Q2	$24K	Hold	179	–	–	﹤0.01%	710
2014 Q1	$28K	Hold	179	–	–	﹤0.01%	687
2013 Q4	$32K	Hold	179	–	–	﹤0.01%	619
2013 Q3	$40K	Hold	179	–	–	﹤0.01%	586
2013 Q2	$32K	Buy	+179	New	+$46.7K	﹤0.01%	615

Other funds holding MDGL

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Evercore Wealth Management's MDGL Position: Q1 2018 in Review

Evercore Wealth Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2018, closing a stake of 354 shares — an estimated $32K sold.

Evercore Wealth Management first reported a position in MDGL in Q2 2013 and held it in 19 quarters. The position peaked at $40K in Q3 2013. 100 funds tracked by Wall St. Rank hold MDGL as of Q1 2018.

Evercore Wealth Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Evercore Wealth Management sold 354 Madrigal Pharmaceuticals shares in Q1 2018, an estimated $32K.
Evercore Wealth Management first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 19 quarters.
Evercore Wealth Management's Madrigal Pharmaceuticals position peaked at $40K in Q3 2013.
100 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2018.

Based on Evercore Wealth Management's 13F filing for Q1 2018, filed 15 May 2018.